Suggestions
Chris Panjwani
Director, Pricing Strategy at Novartis
Chris Panjwani is a seasoned pricing and market access strategist with a strong background in advising on product launch and pricing strategies, conducting payer research, and market segmentation.
With a decade of experience in the industry, Chris is well-versed in US regulatory/payer systems and EU5 health technology assessment (HTA) processes.
His expertise spans across various therapeutic areas including general medicines and oncology, covering conditions like migraine, psoriasis, pulmonary arterial hypertension, Parkinson's, epilepsy, NSCLC, bladder cancer, and renal cell carcinoma.
He holds an impressive educational background with an MBA from Columbia Business School, coupled with a BSE and MSE in biomedical engineering from the University of Michigan.
Chris's strong verbal and written communication skills have been sharpened through numerous consulting and client-side engagements.
Having held key positions at reputable organizations such as Novartis, QuintilesIMS, EY, and Merck, he brings a wealth of knowledge in manufacturing, R&D, and commercial functions to the table.
